Close Menu

NEW YORK (GenomeWeb) – NeoGenomics has commenced an underwritten public offering of approximately $125 million of newly issued shares of common stock.

The company intends to grant underwriters a 30-day option to purchase up to an aggregate of an additional 15 percent of the shares offered in the public offering.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.